{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:46:58Z","timestamp":1791269218793,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.tracli.2006.11.001","type":"journal-article","created":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T07:12:28Z","timestamp":1169622748000},"page":"320-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Current strategies to\u00a0prevent transmission of\u00a0prions by\u00a0human plasma derivatives"],"prefix":"10.1016","volume":"13","author":[{"given":"T.","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2006.11.001_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","author":"Burnouf","year":"2007","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.tracli.2006.11.001_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt\u2013Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.001_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt\u2013Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib4","unstructured":"WHO. WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. http:\/\/www.who.int\/bloodproducts. 2006."},{"key":"10.1016\/j.tracli.2006.11.001_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphoreticular prion protein accumulation in UK tissue samples","volume":"203","author":"Hilton","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.tracli.2006.11.001_bib6","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.38804.511644.55","article-title":"Variant Creutzfeldt\u2013Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study","volume":"332","author":"Ironside","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.tracli.2006.11.001_bib7","unstructured":"WHO. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. www.WHO.int. Geneva; 2003. 1\u201372 p."},{"key":"10.1016\/j.tracli.2006.11.001_bib8","unstructured":"WHO. Recommendations for the production, quality control and regulation of plasma for fractionation. http:\/\/www.who.int\/bloodproducts. 2005."},{"key":"10.1016\/j.tracli.2006.11.001_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro1492","article-title":"Pathogenesis of prion diseases: current status and future outlook","volume":"4","author":"Aguzzi","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tracli.2006.11.001_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tmrv.2006.03.007","article-title":"An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt\u2013Jakob disease","volume":"20","author":"Cervia","year":"2006","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.tracli.2006.11.001_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy","volume":"9","author":"Foster","year":"1999","journal-title":"Transfus. Med."},{"key":"10.1016\/j.tracli.2006.11.001_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nature03989","article-title":"The most infectious prion protein particles","volume":"437","author":"Silveira","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2006.11.001_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev."},{"key":"10.1016\/j.tracli.2006.11.001_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/tvjl.1999.0406","article-title":"Inactivation of transmissible degenerative encephalopathy agents: a review","volume":"159","author":"Taylor","year":"2000","journal-title":"Vet. J."},{"key":"10.1016\/j.tracli.2006.11.001_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1751-2824.2006.00037.x","article-title":"Prion removal with filters","volume":"1","author":"Prowse","year":"2006","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.tracli.2006.11.001_bib16","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1537-2995.2006.00865.x","article-title":"Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands","volume":"46","author":"Gregori","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(00)02719-7","article-title":"Transmission of BSE by blood transfusion in sheep","volume":"356","author":"Houston","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.001_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1126\/science.1132661","article-title":"Infectious prions in the saliva and blood of deer with chronic wasting disease","volume":"314","author":"Mathiason","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tracli.2006.11.001_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1126\/science.1129051","article-title":"Presymptomatic detection of prions in blood","volume":"313","author":"Saa","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tracli.2006.11.001_bib21","first-page":"2","article-title":"Isolation from cattle of a prion strain distinct from that causing bovine spongiform encephalopathy","volume":"10","author":"Beringue","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tracli.2006.11.001_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1751-2824.2006.00006.x","article-title":"Controlling the blood-borne spread of human prion disease","volume":"1","author":"Prowse","year":"2006","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.tracli.2006.11.001_bib23","unstructured":"Afssaps. Analyse du risque de transmission de la variante de la maladie de Creutzfeldt\u2013Jakob par les m\u00e9dicaments d'origine humaine et par les produits sanguins labiles\u2014actualisation des donn\u00e9es du rapport du groupe ad hoc de d\u00e9cembre 2000. Saint-Denis, France: Afssaps; rapport de mars 2003 (1\u201322p)."},{"key":"10.1016\/j.tracli.2006.11.001_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1423-0410.2003.00288.x","article-title":"Quality assessment of seven types of fresh-frozen plasma leucoreduced by specific plasma filtration","volume":"84","author":"Chabanel","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib25","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1046\/j.1537-2995.2003.00543.x","article-title":"Residual cell content in plasma from 3 centrifugal apheresis procedures","volume":"11","author":"Burnouf","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/37789","article-title":"A crucial role for B cells in neuroinvasive scrapie","volume":"390","author":"Klein","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2006.11.001_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.001_bib28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1537-2995.1999.39111169.x","article-title":"Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt\u2013Jakob disease in humans","volume":"39","author":"Brown","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1423-0410.2000.7940248.x","article-title":"Validation of prion removal by leucocyte-depleting filters: a cautionary tale","volume":"79","author":"Prowse","year":"2000","journal-title":"Vox Sang."},{"issue":"supplement","key":"10.1016\/j.tracli.2006.11.001_bib30","first-page":"109A","article-title":"Evaluation of a new combination filter for prion and leukoreduction (LR) of red cell concentrates (RCC)","volume":"46","author":"Miura","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0378-4347(94)00532-A","article-title":"Chromatography in plasma fractionation: benefits and future trends","volume":"664","author":"Burnouf","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.tracli.2006.11.001_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0165-022X(01)00221-4","article-title":"Affinity chromatography in the industrial purification of plasma proteins for therapeutic use","volume":"49","author":"Burnouf","year":"2001","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.tracli.2006.11.001_bib33","unstructured":"CPMP. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (revised). CPMP\/BWP\/CPMP\/5136\/03. http:\/\/www.emea.eu.int. London: European Agency for the Evaluation of Medicinal Products (EMEA); 1996."},{"key":"10.1016\/j.tracli.2006.11.001_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/biol.2002.0327","article-title":"Purity of spiking agent affects partitioning of prions in plasma protein purification","volume":"30","author":"Vey","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2006.11.001_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.2001.0269","article-title":"Scrapie removal using Planova virus removal filters","volume":"29","author":"Tateishi","year":"2001","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2006.11.001_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1423-0410.2002.00211.x","article-title":"Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin","volume":"83","author":"Reichl","year":"2002","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib38","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1046\/j.1537-2995.2002.00216.x","article-title":"Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma","volume":"42","author":"Stenland","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy","volume":"38","author":"Brown","year":"1998","journal-title":"Transfusion"},{"issue":"Suppl 2","key":"10.1016\/j.tracli.2006.11.001_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1741-6892.2004.00444.x","article-title":"Removal of TSE agents from blood products","volume":"87","author":"Foster","year":"2004","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1537-2995.2001.41040449.x","article-title":"A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins","volume":"41","author":"Lee","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib42","first-page":"S45","article-title":"\u00c9valuation de l\u2019efficacit\u00e9 des proc\u00e9d\u00e9s de purification des proteins plasmatiques \u00e0 \u00e9liminer les agents transmissibles non conventionnels","volume":"9","author":"Flan","year":"2005","journal-title":"Virologie"},{"key":"10.1016\/j.tracli.2006.11.001_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","article-title":"Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein","volume":"84","author":"Lee","year":"2000","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.tracli.2006.11.001_bib44","unstructured":"Flan B. Tissue culture system for TSE detection in process studies. 2006 April 11\u201312. 2006; Paris: International Plasma Fractionation Association."},{"key":"10.1016\/j.tracli.2006.11.001_bib45","doi-asserted-by":"crossref","first-page":"35245","DOI":"10.1074\/jbc.M603964200","article-title":"Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification","volume":"46","author":"Saa","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tracli.2006.11.001_bib46","first-page":"8","article-title":"A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography","volume":"60","author":"Burnouf","year":"1991","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib47","first-page":"225","article-title":"Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography","volume":"57","author":"Burnouf","year":"1989","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0042-9007.2004.00403.x","article-title":"Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII","volume":"86","author":"Foster","year":"2004","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib49","first-page":"20","article-title":"Validation de l'efficacit\u00e9 des \u00e9tapes de fractionnement du plasma dans l'\u00e9limination des ATNC","volume":"13","author":"Flan","year":"2001","journal-title":"Sang Thrombose Vaisseaux"},{"key":"10.1016\/j.tracli.2006.11.001_bib50","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood.V106.11.4177.4177","article-title":"Solvent-detergent treatment and ion-exchange chromatography have no impact on prion removal by 15\u00a0nm nanofiltration in the manufacture of Factane\u00ae. Blood (American Society of Hematology Annual Meeting Abstracts)","volume":"106","author":"Porte","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2006.11.001_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/157341305774642894","article-title":"Place of nanofiltration for assuring viral safety of biologicals","volume":"1","author":"Burnouf","year":"2005","journal-title":"Current Nanoscience"},{"key":"10.1016\/j.tracli.2006.11.001_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2006.11.001_bib53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5360\/membrane.18.357","article-title":"Removal of causative agent of Creutzfeldt\u2013Jakob disease (CJD) through membrane filtration method","volume":"18","author":"Tateishi","year":"1993","journal-title":"Membrane"},{"key":"10.1016\/j.tracli.2006.11.001_bib54","series-title":"Proceedings of the Fourth Meeting of the FDA Advisory Committee on Transmissible Spongiform Encephalopathies","article-title":"Experimental studies of blood infected with TSE agents","author":"Rohwer","year":"1998"},{"key":"10.1016\/j.tracli.2006.11.001_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1423-0410.2003.00312.x","article-title":"Evaluation of depth filtration to remove prion challenge from an immune globulin preparation","volume":"85","author":"Van Holten","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1423-0410.2003.00279.x","article-title":"Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process","volume":"84","author":"Trejo","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jhin.2006.06.007","article-title":"Quantitative evaluation of prion inactivation comparing steam sterilization and chemical sterilants: proposed method for test standardization","volume":"64","author":"Vadrot","year":"2006","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.tracli.2006.11.001_bib58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(04)16810-4","article-title":"Novel methods for disinfection of prion-contaminated medical devices","volume":"364","author":"Fichet","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.001_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1423-0410.2006.00790.x","article-title":"Critical factors influencing prion inactivation by sodium hydroxide","volume":"91","author":"Bauman","year":"2006","journal-title":"Vox Sang."},{"key":"10.1016\/j.tracli.2006.11.001_bib60","article-title":"Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie","author":"Unal","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2006.11.001_bib61","unstructured":"Flan B. Evaluation of TSE removal procedures in the manufacture of plasma products. WHO Consultation on Tissue Infectivity Distribution in TSEs. 2005 14\u201316 September. 2005; Geneva: World Health Organization."},{"key":"10.1016\/j.tracli.2006.11.001_bib62","unstructured":"Losikoff A. Retention of TSE infectivity by Planova nanofilters as function of spike composition. In: IBC USA Conference Prions: Assessment and management of risks from blood-borne TSE infectivity. 2001 April 2. 2001; Westborough, USA: IBC USA Conference."},{"key":"10.1016\/j.tracli.2006.11.001_bib63","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1046\/j.1537-2995.2002.00160.x","article-title":"Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter","volume":"42","author":"Van Holten","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2006.11.001_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2003.08.004","article-title":"Partitioning of TSE infectivity during ethanol fractionation of human plasma","volume":"32","author":"Gregori","year":"2004","journal-title":"Biologicals"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782006001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782006001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:27:56Z","timestamp":1761128876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782006001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1246782006001431"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2006.11.001","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current strategies to\u00a0prevent transmission of\u00a0prions by\u00a0human plasma derivatives","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2006.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}